Bristol Myers Sqibb News (NYSE:BMY)

DateTimeSource
Headline
10/16/20174:15PMBWU.S. Food & Drug Administration (FDA) Accepts Bristol-Myers Squibb’s Application for Opdivo (nivolumab) in Patients with Re...
Opdivo also previously received FDA Breakthrough Therapy Designation, the seventh time Opdivo has received the designation Application based on results from Phase 3 CheckMate -238 study Bristol-Myers Squibb Company (NYSE: BMY) announced today that the U.S. Food and Drug Administration (FDA) has accepted for priority review... More...>>
10/16/20173:15AMBWOpdivo Alone or Combined with Yervoy Shows Encouraging Response & Survival Rates in Recurrent Small Cell Lung Cancer Patients...
Overall response rate with Opdivo was 21%, and more than double with the Opdivo plus Yervoy combination (46%), in patients with high tumor mutation burden Overall survival rate with Opdivo at one year was 35%, and nearly double with the Opdivo plus Yervoy combination (62%), in patients with high tumor mutation burden First... More...>>
10/12/20179:00AMPRNUSBristol-Myers Squibb (BMY) Extends Strategic Partnership with TARGET PharmaSolutions for TARGET-NASH
Bristol-Myers Squibb (BMY) Extends Strategic Partnership with TARGET PharmaSolutions for TARGET-NASH PR Newswire CHAPEL HILL, N.C, Oct. 12, 2017 CHAPEL HILL, N.C, Oct. 12, 2017 /PRNewswire/ -- TARGET PharmaSolutions, Inc., a real-world clinical data company, is pleased to announce that Bristol-Myers Squibb (BMY) has extended... More...>>
10/09/20176:59AMBWBristol-Myers Squibb Appoints Saurabh Saha, M.D., Ph.D., as Senior Vice President, Global Head of Translational Medicine
Bristol-Myers Squibb Company (NYSE: BMY) announced that it has appointed scientific and business thought-leader, Saurabh Saha, M.D., Ph.D., as senior vice president and global head of translational medicine in the company’s R&D organization, effective today. “Enhancing our translational medicine capability is critical... More...>>
10/04/20176:59AMBWCaregivers Wish Liver Cancer Received Greater Public Awareness in the U.S., New Survey Reveals
National survey, released in recognition of Liver Cancer Awareness Month, identifies gaps in knowledge around the disease, research and support among caregivers of people with liver cancer New online resource, LiverCancerOutlook.com, provides valuable information for people with liver cancer and their caregivers Bristol-Myers... More...>>
09/27/20175:00PMBWBristol-Myers Squibb: Advancing Research Across Thoracic Cancers with New Data at IASLC 18th World Conference on Lung Cancer
Bristol-Myers Squibb Company (NYSE: BMY) today announced the presentation of 28 abstracts for Opdivo (nivolumab), alone and in combination with Yervoy (ipilimumab), targeted therapy or chemotherapy, at the International Association for the Study of Lung Cancer (IASLC) 18th World Conference on Lung Cancer (WCLC) in Yokohama... More...>>
09/22/20176:10PMBWBristol-Myers Squibb’s Opdivo® (nivolumab) Receives FDA Approval for the Treatment of Hepatocellular Carcinoma Patients Pr...
Opdivo is the first and only Immuno-Oncology agent to receive this FDA approval; this accelerated approval is based on tumor response rate and durability of response in these patients The CheckMate -040 pivotal study evaluated Opdivo in patients with and without active Hepatitis B or C infection, and across PD-L1 expression... More...>>
09/22/20177:00AMPRNUSAbbVie and Bristol-Myers Squibb Announce Clinical Research Collaboration to Evaluate a Therapeutic Regimen in Advanced Solid ...
AbbVie and Bristol-Myers Squibb Announce Clinical Research Collaboration to Evaluate a Therapeutic Regimen in Advanced Solid Tumors PR Newswire NORTH CHICAGO, Ill. and NEW YORK, Sept. 22, 2017 NORTH CHICAGO, Ill. and NEW YORK, Sept. 22, 2017 /PRNewswire/ -- AbbVie (NYSE: ABBV) and Bristol-Myers Squibb Company (NYSE: BMY... More...>>
09/22/20176:59AMBWAbbVie & Bristol-Myers Squibb Announce Clinical Research Collaboration to Evaluate a Therapeutic Regimen in Advanced Solid Tu...
AbbVie (NYSE: ABBV) and Bristol-Myers Squibb Company (NYSE: BMY) today announced a clinical trial collaboration to evaluate the combination of AbbVie’s investigational antibody drug conjugate ABBV-399 and Bristol-Myers Squibb’s immunotherapy Opdivo (nivolumab) in c-Met overexpressing non-small cell lung cancer (NSCLC... More...>>
09/22/20175:00AMBWJapan Ministry of Health, Labor & Welfare Approves Opdivo (nivolumab) for the Treatment of Patients with Unresectable Advance...
Opdivo is the first and only Immuno-Oncology treatment to demonstrate survival benefit in patients who underwent two or more prior treatments Opdivo is the first Immuno-Oncology agent anywhere in the world to receive approval for unresectable advanced or recurrent gastric cancer based on a Phase 3 study Bristol-Myers Squibb... More...>>
09/21/20176:59AMBWBristol-Myers Squibb to Take Part in Leerink Partners Rare Disease & Immuno-Oncology Roundtable Conference
Bristol-Myers Squibb Company (NYSE:BMY) will take part in Leerink Partners Rare Disease & Immuno-Oncology Roundtable Conference on Thursday, September 28, 2017, in New York. Thomas Lynch, chief scientific officer, will answer questions about the company at 11:00 a.m. EDT. Investors and the general public are invited... More...>>
09/21/20176:59AMBWNew Global Report Finds Majority of People at High Risk of Stroke Not Being Screened for Common Risk Factors
The Economist Intelligence Unit research identifies significant gaps between recommended guidelines and clinical practice for stroke prevention across 20 countries New research released today by The Economist Intelligence Unit (EIU), a division of The Economist and a leader in global business intelligence, revealed that... More...>>
09/14/20176:59AMBWBristol-Myers Squibb and Halozyme Enter Global Collaboration and License Agreement for ENHANZE Technology
Bristol-Myers Squibb is Committed to Enhancing Patient Care Through Delivery of Cancer Treatments by Subcutaneous Injection Halozyme to Receive $105 Million Upfront Payment, Plus Future Milestones and Royalties Provides Bristol-Myers Squibb Access to ENHANZE technology for up to 11 Targets Bristol-Myers Squibb Company... More...>>
09/13/20174:30PMBWBristol-Myers Squibb Announces Dividend
The Board of Directors of Bristol-Myers Squibb Company (NYSE:BMY) today declared a quarterly dividend of thirty-nine cents ($0.39) per share on the $.10 par value Common Stock of the corporation. The next quarterly dividend will be payable on November 1, 2017, to stockholders of record at the close of business on October... More...>>
09/13/20174:15PMBWBristol-Myers Squibb Names Karen Vousden, Ph.D. to Board of Directors
Bristol-Myers Squibb Company (NYSE:BMY) today announced that its Board of Directors has elected Karen Vousden, Ph.D., to the Board, effective January 1, 2018. Dr. Vousden will serve as a member of the Science and Technology Committee of the Board of Directors. Dr. Vousden, 60, is currently group leader at the Francis Crick... More...>>
09/10/20176:11PMBWOpdivo (nivolumab) Demonstrates Superior Recurrence-Free Survival Versus Yervoy (ipilimumab) for Patients with Resected High-...
Opdivo decreased the risk of disease recurrence by 35% compared to Yervoy Opdivo is the first anti-PD-1 to improve RFS and only I-O therapy to demonstrate superiority versus an active control in this patient population Adjuvant treatment with Opdivo was well tolerated, with 14% of patients experiencing grade 3/4 adverse... More...>>
09/10/201711:55AMBWOpdivo Plus Yervoy Combination Demonstrated Superior Overall Survival & Showed Durable Responses in Patients with Previously ...
Opdivo (nivolumab) plus Yervoy (ipilimumab) reduced the risk of death by 37% versus standard of care, sunitinib, in intermediate- and poor-risk patients The combination also significantly improved overall survival in all randomized patients Opdivo plus Yervoy demonstrated a 42% objective response rate in intermediate... More...>>
09/08/20175:30AMBWTwo Pivotal Opdivo (nivolumab) Trials Show Three-Year Survival Benefit in Patients with Previously Treated Advanced Non-Small...
Data continued to show benefit with Opdivo in overall population, with nearly triple (CheckMate -017) and double (CheckMate -057) the patients alive at three years compared to docetaxel Results represent the longest Phase 3 follow-up data reported for a PD-1 inhibitor in second-line non-small cell lung cancer Safety profile... More...>>
09/07/20174:30PMBWBristol-Myers Squibb Completes Previously Announced Acquisition of IFM Therapeutics
Bristol-Myers Squibb Company (NYSE:BMY) today announced that it has completed the previously announced planned acquisition of IFM Therapeutics. The transaction includes full rights to IFM’s preclinical STING (stimulator of interferon genes) and NLRP3 agonist programs focused on enhancing the innate immune response for... More...>>
09/07/20176:59AMBWBristol-Myers Squibb to Announce Results for Third Quarter 2017 on October 26
Bristol-Myers Squibb Company (NYSE:BMY) will announce results for the third quarter of 2017 on Thursday, October 26, 2017. During a conference call at 10:30 a.m. EDT on October 26, company executives will review financial information and will address inquiries from investors and analysts. Investors and the general public... More...>>
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:43 V:us D:20171017 03:57:22